Market Size of Gastroesophageal Reflux Disease Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Gastroesophageal Reflux Disease (GERD) Market Analysis
The gastroesophageal reflux disease market is poised to grow at a CAGR of 4.3% over the forecast period.
The COVID-19 pandemic impacted the market owing to supply chain disruptions due to lockdown restrictions in its initial phases. Also, the eating habits of people worldwide were affected due to the lockdown and isolation and people had started overeating which has resulted in high cases of gastroesophageal reflux diseases (GERD). Also, research studies indicated that COVID-19 severely impacted people with GERD. For instance, an article published in Human Molecular Genetics Journal in February 2022 stated that symptoms related to GERD were observed to be linked with a high risk for COVID-19. Therefore, the COVID-19 has led to an increase in demand for GERD medications during pandemic. Hence, the market witnessed a significant growth during the pandemic period.
Factors such as the rising prevalence of gastrointestinal reflux diseases, changing lifestyles, and increasing awareness about GERD are expected to fuel the market growth during the analysis period.
According to an article updated in July 2022 by the National Library of Medicine, GERD is one of the most prevalent chronic gastrointestinal disorders which affects about 20% of individuals in western culture and is defined by the regurgitation of gastric contents into the esophagus. Thus, this common condition among the target population is expected to increase awareness about the disease leading to diagnosis and treatment for the same. Thereby, it is expected to drive market growth over the forecast period.
Additionally, according to an article updated by the National Center for Biotechnology Information (NCBI) in May 2022, tobacco smoking is considered an etiological factor of reflux esophagitis or acid reflux and it is considered a major risk factor for acid reflux over the age of 50. Also, as per the article published in November 2021 by NCBI, the recent epidemiological studies stated that there is increasing GERD prevalence worldwide and the estimated prevalence of GERD ranged from 15% to 25%, while Saudi Arabia had GERD prevalence between 15% - 45.4%, Western Asia with 10%-20%, the Middle East with 8.7%-33.1%, and Eastern Asia reported less than 10% prevalence during the study. The high prevalence of the tobacco smoking and GERD is projected to boost the demand for the availability of drugs and diagnoses for the target population which is further predicted to contribute to market growth.
Furthermore, the development activities by the market players in the form of product launches, mergers, acquisitions, and investments are also expected to enhance the market growth. For instance, in October 2021, Medical City Frisco opened a new heartburn and reflux center making it the only one of its kind in Collin and Dallas counties. The Heartburn & Reflux Center offers minimally invasive robotic and laparoscopic treatment options for gastroesophageal reflux disease (GERD) and oesophageal disorders including transoral incisionless fundoplication (TIF). Such advancements are expected to drive the market to grow in the future.
Therefore, owing to the above-mentioned factors the market studied is expected to grow over the forecast period. However, the expiration of patents for blockbuster drugs and frequent product recalls are the factors are anticipated to restrain the market growth over the forecast period.
Gastroesophageal Reflux Disease (GERD) Industry Segmentation
As per the scope of this report, gastroesophageal reflux disease (GERD) is a disorder in which the lower oesophageal sphincter is affected and causes the backflow of contents from the stomach to the esophagus. The major causes of gastroesophageal reflux disease include obesity, smoking, and sedentary lifestyle habits. The Gastroesophageal Reflux Disease Market is Segmented by Diagnosis (Upper Endoscopy, Ambulatory Acid (pH) Probe Test, Esophageal Manometry, and Others), Drug Type (Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Diagnosis | |
| Upper Endoscopy | |
| Ambulatory Acid (pH) Probe Test | |
| Esophageal Manometry | |
| Others |
| By Drug Type | |
| Proton Pump Inhibitors (PPIs) | |
| H2 Receptor Blockers | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Gastroesophageal Reflux Disease Market Size Summary
The gastroesophageal reflux disease (GERD) market is expected to experience steady growth over the forecast period, driven by factors such as the increasing prevalence of GERD, changing lifestyles, and heightened awareness of the condition. The COVID-19 pandemic initially disrupted the market due to supply chain issues and altered eating habits, which led to a rise in GERD cases. This situation, coupled with research linking GERD symptoms to a higher risk of COVID-19, spurred demand for GERD medications during the pandemic. The condition's widespread nature, particularly in Western cultures, is anticipated to further raise awareness and prompt diagnosis and treatment, thereby fueling market expansion. Additionally, the prevalence of tobacco smoking as a risk factor for GERD, especially among older adults, is expected to contribute to the demand for drugs and diagnostics, supporting market growth.
The market is characterized by the presence of numerous players engaged in strategic activities such as product launches, mergers, and acquisitions to enhance their market presence. The development of advanced therapeutics and the introduction of cost-effective generic drugs, such as H2-receptor blockers, are key factors driving segment growth. North America, particularly the United States, is projected to witness significant growth due to increased healthcare expenditure, rising research and development activities, and a growing geriatric population. The high prevalence of GERD in the region presents opportunities for advanced treatments, further propelling market growth. Despite challenges like patent expirations and product recalls, the market's fragmented nature and ongoing strategic initiatives by key players are expected to sustain its growth trajectory.
Gastroesophageal Reflux Disease Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Gastrointestinal Reflux Diseases and Changing Lifestyle
-
1.2.2 Increasing Awareness about GERD
-
-
1.3 Market Restraints
-
1.3.1 Patent Expiry of Blockbuster Drugs and Frequent Product Recalls
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Diagnosis
-
2.1.1 Upper Endoscopy
-
2.1.2 Ambulatory Acid (pH) Probe Test
-
2.1.3 Esophageal Manometry
-
2.1.4 Others
-
-
2.2 By Drug Type
-
2.2.1 Proton Pump Inhibitors (PPIs)
-
2.2.2 H2 Receptor Blockers
-
2.2.3 Others
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Gastroesophageal Reflux Disease Market Size FAQs
What is the current Global Gastroesophageal Reflux Disease Market size?
The Global Gastroesophageal Reflux Disease Market is projected to register a CAGR of 4.30% during the forecast period (2024-2029)
Who are the key players in Global Gastroesophageal Reflux Disease Market?
Pfizer, Inc., Johnson & Johnson, SRS Life Sciences, Takeda Pharmaceutical Co., Ltd. and Haleon Group of Companies are the major companies operating in the Global Gastroesophageal Reflux Disease Market.
